(1) Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (2) 2007 addend(1) Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (2) 2007 addendum.National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Sep. 62 p. (Technology appraisal guidance; no. 111).Twenty-one published economic evaluations of the three acetylcholinesterase (AChE) inhibitors and memantine were available to the Appraisal Committee. All four manufacturers also submitted their own economic evaluations. The Assessment Group reran each of the manufacturer's economic models using its preferred assumptions, and it also presented an additional economic evaluation of the three AChE inhibitors. Further analyses were undertaken by the National Institute for Health and Clinical Excellence (NICE) secretariat as described in technical report number 1 and the addendum of the Assessment Report (see the Availability of Companion Documents field).
